Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Joong‐Won Park(National Cancer Center), Won Young Tak(Kyungpook National University Hospital), Deng‐Yn Lin(Samsung Medical Center), Yee Chao(National Cancer Center), Masatoshi Kudo(Kindai University), Eric Assénat, Valérie Boige(Inserm), Lætitia Fartoux(Asan Medical Center), Éveline Boucher(Boston Scientific (United States)), Morris Sherman(University Health Network), Rana Ezzeddine(Institut Claudius Regaud), Ho-Yeong Lim(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Thomas Decaens(Centre National de la Recherche Scientifique), Richard S. Finn(University of California, Los Angeles), Jean‐Luc Raoul(Institut de Cancérologie de l'Ouest), Jordi Bruix(Hospital Clínic de Barcelona), Jean‐Frédéric Blanc, David Liu(Bristol-Myers Squibb (Germany)), Philippe Mathurin(Centre Hospitalier Universitaire de Lille), Ian Walters(Bristol-Myers Squibb (Germany)), Yoon‐Koo Kang(Ulsan College), Ronnie T.P. Poon(University of Hong Kong), Charissa Chang(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 596
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k